Parkinson's Disease Inflammatory Biomarker Profiling
- Conditions
- Parkinson Disease
- Registration Number
- NCT03633513
- Lead Sponsor
- Longevity Biotech
- Brief Summary
This study compares a comprehensive panel of immunological biomarkers between Parkinson's disease patients and healthy, environmentally matched participants. This unique study design provides the ability to control for differences in environment between study subjects. The goal of this study is to 1) identify a specific set of immunological markers that correlate with a clinical diagnosis of Parkinson's disease and 2) stratify patients by disease severity using these same biomarkers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 99
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Unified Parkinson Disease Rating Scale 1 hour Clinical scoring system to evaluate severity of Parkinson's disease in patients
- Secondary Outcome Measures
Name Time Method Interferon gamma 48 hours Inflammatory cytokine
FoxP3 48 hours Regulatory Tcell marker
GM-CSF 48 hours Cytokine
VPAC2 48 hours Regulates TH1/TH2 balance of inflammatory system
Tumor necrosis factor alpha 48 hours Inflammatory cytokine
LRRK2 48 hours Leucine rich region kinase 2 protein
Interleukin-17 48 hours Proinflammatory cytokine
Trial Locations
- Locations (2)
Corporal Michael J. Crescenz VA Medical Center
🇺🇸Philadelphia, Pennsylvania, United States
Longevity Biotech, Inc
🇺🇸Philadelphia, Pennsylvania, United States
Corporal Michael J. Crescenz VA Medical Center🇺🇸Philadelphia, Pennsylvania, United States